Angle PLC - Surrey, England-based medical diagnostics company - Receives approval from the US Food & Drug Administration for the use of its Parasortix system for use in metastatic breast cancer patients. Parasortix isolates circulating tumour cells from the blood which can aid in the diagnosis, characterisation and monitoring of cancer, and do so in a much less invasive fashion than traditional tissue biospy.

Angle hailed the decision as ‘the first ever FDA product clearance to harvest cancer cells from a patient blood sample for subsequent analysis and offers the prospect of a new era of personalised cancer care’, which would give it ‘first mover’ advantage for intact cell analysis in the global liquid biopsy market, which is estimated to grow to $100 billion in the US.

Current stock price: 155.00p, up 57% on Wednesday

12-month change: up 14%

Copyright 2022 Alliance News Limited. All Rights Reserved.